Furthermore, it also identified an informative molecular signature associated with non-leukemic hematopoietic stem/progenitor cells (HSPCs) (BCR-ABL negative cells from CML patients) at diagnosis, which was shown to be predictive for subsequent therapy resistance. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.